The purpose of this review is to demonstrate the potential for development of coagulation-
reactive drugs for experimental cancer treatment. Improved cancer outcome has been …

This overview of the coagulation biology of cancer is intended primarily for those unfamiliar
with the link between the coagulation mechanism and neoplasia. Because the literature on …

Rapid progress has been made recently in our understanding of the pathogenesis of
coagulation activation in malignancy and mechanisms by which the coagulation mechanism …

It has been known for over a century that blood coagulation and fibrinolysis pathways are
activated systemically in patients with malignancy. Recent studies have revealed evidence …

Critical information on the nature of the coagulation-cancer interaction has been obtained
from a number of sources. In vitro/ex vivo sources of information include assays performed …

The association between thrombosis and cancer is well known and the first description of
venous thrombosis as a complication of malignant disease by Trousseau dates back to …

Clinical trials of drugs that influence coagulation and fibrinolysis pathways have been
undertaken in patients with malignancy because these pathways are capable of influencing …

The association between cancer and activation of blood coagulation has been described
since Trousseau's time. The hypercoagulable state often encountered in cancer patients not …

Venous thromboembolism is a common complication in patients with malignant disease. It is
associated with a systemic hypercoagulable state that is secondary to tumor elaboration of …

The blood coagulation mechanism regulates the growth and dissemination of malignancy by
multiple mechanisms, and anticoagulant drugs have been shown to inhibit the progression …